Updated Jul 16, 2026
Chow Gregory K. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $16K.
Gregory K. Chow is the Chief Financial Officer (CFO) of Sutro Biopharma, Inc., a clinical-stage biopharmaceutical company focused on developing protein therapeutics for cancer and autoimmune disorders. He has been involved in the company's financial operations and reporting.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-02 | STRO | SUTRO BIOPHARMA, INC. | M — Option exercise | 2.5K | $0.00 | |
| 2025-10-15 | STRO | SUTRO BIOPHARMA, INC. | P — Open-market purchase | 19.8K | $0.81 | $16K |
Gregory K. Chow is the Chief Financial Officer (CFO) of Sutro Biopharma, Inc., a clinical-stage biopharmaceutical company focused on developing protein therapeutics for cancer and autoimmune disorders. He has been involved in the company's financial operations and reporting.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($16K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Chow Gregory K. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.